Document is current
Any future updates will be listed below
-
Authors
Labrie, Marilyne https://orcid.org/0000-0003-3957-5533
Brugge, Joan S.
Mills, Gordon B. https://orcid.org/0000-0002-0144-9614
Zervantonakis, Ioannis K. https://orcid.org/0000-0003-2386-9553
- License Information
-
More Information
Article History
Accepted: 9 February 2022
First Online: 9 March 2022
Competing interests
: M.L., I.K.Z. and J.S.B. have no conflicts of interest relating to the topics in this Review. G.B.M. has acted as a consultant or scientific advisory board member for AstraZeneca, Ellipses Pharma, ImmunoMET, Infinity, Ionis, Lilly, Nanostring, PDX Pharmaceuticals, Signalchem Lifesciences, Tarveda, Turbine and Zentalis Pharmaceuticals, and holds stock or stock options for Catena Pharmaceuticals, ImmunoMet, SignalChem, Spindletop Ventures, Tarveda and Turbine. G.B.M. has licensed technology including HRD assay (Myriad Genetics) and DSP (Nanostring).
